ALK and non-small cell lung carcinoma: In this study, we performed an NMA that included six treatment arms: lorlatinib, brigatinib, alectinib, ceritinib, crizotinib, and chemotherapy with the main objective of comparing the efficacy and safety of lorlatinib and alectinib in ALK-p ALK-inhibitor-naïve advanced NSCLC patients.